Specialized Disclosure Report (sd)
25 May 2018 - 10:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
MERIDIAN BIOSCIENCE, INC.
(Exact name of the registrant as specified in its charter)
Ohio
|
|
0-14902
|
|
31-0888197
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
3471 River Hills Drive
Cincinnati, Ohio
|
|
|
|
45244
|
(Address of principal executive offices)
|
|
|
|
(Zip code)
|
Melissa A. Lueke
|
|
(513) 271-3700
|
(Name and telephone number, including area code, of
the person to contact in connection with this report.)
|
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
X
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.
___ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _____________________________.
SECTION 1. CONFLICT MINERALS DISCLOSURE
Item 1.01
Conflict Minerals Disclosure and Report
Meridian Bioscience, Inc. ("Meridian" or the "Company") evaluated its products during the year ended December 31, 2017 and determined that certain products manufactured or contracted to be manufactured by the Company contain tin, tungsten, tantalum, and/or gold. As a result, Meridian has filed a Conflict Minerals Report ("CMR"). A copy of Meridian's CMR is furnished as Exhibit 1.01 to this Form SD and is incorporated herein by reference. Copies of Meridian's Form SD and CMR are also available at the Meridian corporate website:
www.meridianbioscience.com
.
SECTION 2. EXHIBITS
Item 2.01
Exhibits
Exhibit 1.01
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
Date: May 25
,
2018
|
MERIDIAN BIOSCIENCE, INC.
By:
/s/ Melissa A. Lueke
Melissa A. Lueke
Executive Vice President and
Chief Financial Officer
|
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Meridian Bioscience Inc (NASDAQ): 0 recent articles
More Meridian Bioscience Inc News Articles